Sestamibi parathyroid scintigraphy in multigland disease

Area of Science:

• Nuclear Medicine
• Endocrinology
• Surgical Oncology

Background:

• Primary hyperparathyroidism diagnosis relies on imaging for localization.
• Sestamibi (MIBI) scintigraphy is a common preoperative localization tool.
• Conflicting reports exist regarding MIBI sensitivity in multigland disease (MGD) versus single-gland disease (SGD).

Purpose of the Study:

• To compare MIBI imaging sensitivity and specificity for parathyroid lesions in MGD vs. SGD.
• To investigate the relationship between MIBI sensitivity, lesion number, weight, and location in MGD and SGD.
• To determine if lesion characteristics explain MIBI performance differences in MGD.

Main Methods:

• Retrospective analysis of 651 primary hyperparathyroidism patients undergoing MIBI/TcO4- dual tracer imaging.
• Inclusion of early/late planar pinhole MIBI, thyroid imaging, subtraction, and SPECT.
• Correlation of imaging findings with surgical and pathological data on lesion number, weight, and location.

Main Results:

• MIBI imaging showed significantly lower sensitivity (61% vs. 97%) and specificity (84% vs. 93%) for MGD compared to SGD.
• Lesions in MGD were significantly smaller (median 190 mg vs. 500 mg) and sensitivity decreased with increasing lesion number.
• Lesion weight and location did not fully explain the decreased MIBI sensitivity in MGD.

Conclusions:

• MIBI scintigraphy demonstrates reduced sensitivity and specificity for parathyroid lesions in patients with MGD.
• The diminished performance in MGD is not attributable to lesion weight or spatial distribution.
• Further research is needed to identify factors influencing MIBI imaging accuracy in MGD.